(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Dyne Therapeutics's earnings in 2026 is -$519,406,000.On average, 18 Wall Street analysts forecast DYN's earnings for 2026 to be -$678,412,435, with the lowest DYN earnings forecast at -$721,065,319, and the highest DYN earnings forecast at -$615,702,983. On average, 17 Wall Street analysts forecast DYN's earnings for 2027 to be -$624,255,970, with the lowest DYN earnings forecast at -$829,042,106, and the highest DYN earnings forecast at -$539,230,320.
In 2028, DYN is forecast to generate -$484,737,711 in earnings, with the lowest earnings forecast at -$997,412,688 and the highest earnings forecast at -$147,062,814.